Pharmacodynamic assessments were defined according to P2Y12 reaction unit ( PRU ) ( P2Y12 assay ) and platelet reactivity index ( vasodilator-stimulated phosphoprotein phosphorylation assay ) at baseline ( before and after the run-in phase ) and 2 , 4 , 24 , and 48 h and 7 days after randomization .